Drug WatchFirst Drug Approved for Rare Lung DiseaseAschenbrenner, Diane S. MS, RNAuthor Information Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: firstname.lastname@example.org. AJN, American Journal of Nursing: January 2020 - Volume 120 - Issue 1 - p 25-26 doi: 10.1097/01.NAJ.0000652012.36533.27 Buy Metrics Abstract Nintedanib (Ofev) is the first drug approved for the treatment of SSc-ILD, a rare interstitial lung disease associated with systemic sclerosis or scleroderma. This is a new indication for nintedanib, which was previously approved for idiopathic pulmonary fibrosis. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.